drugset / Trial / NCT04622579
Lenalidomide Combined With Rituximab as Front-line Therapy for DLBCL Patients Aged Over 80 Years
Phase 2
Unknown
20 enrolled
Guangdong Provincial People's Hospital
First People's Hospital of Foshan · collabGuangzhou First People's Hospital · collabHuizhou Municipal Central Hospital · collabShantou Central Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
About 40% of Diffuse large B cell lymphoma relapse or is refractory, age is a prognostic factor of DLBCL, as elderly patients are not capable to received standard treatment, the prognosis of elderly patients is poor especially those aged over 80 years. In this study,we aimed to investigate the safety and efficacy of the combination of lenalidomide and rituximab in elderly patients aged ≥ 80 years with untreated DLBCL.
Timeline
- Start
- 2020-10-23
- Primary completion
- 2022-12-31
- Completion
- 2023-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | 10 mg | Oral |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |